Flowchart of included patients.

Flowchart of included patients.</p

Effect of anti-acid medications on pneumonia risk according to the dose intensity.

Effect of anti-acid medications on pneumonia risk according to the dose intensity.</p

Effects of medications on the risk for post-stroke pneumonia.

Effects of medications on the risk for post-stroke pneumonia.</p

Estimated pneumonia-free probability according to the use of medications during post-stroke follow-up period.

Each plot illustrates estimated pneumonia-free survival curves according to the use of PPI (A), H2RA (B), and mucoprotective agents (C) during the followed-up period after stroke. Mucoprotective agents include rebamipide, teprenone, irsogladine, ecabet, polaprezinc, sofalcone, sucralfate, and misoprostol. Abbreviations: H2RA, H2-receptor antagonist; PPI, proton-pump inhibitor.</p

Proportion of patients who received medications thoughout the post-stroke period.

Mucoprotective agents include rebamipide, teprenone, irsogladine, ecabet, polaprezinc, sofalcone, sucralfate, and misoprostol. Abbreviations: H2RA, H2-receptor antagonist; PPI, proton-pump inhibitor.</p

Baseline characteristics of included patients.

Baseline characteristics of included patients.</p

Clinical characteristics of patients according to current use of medications at 1-year after index stroke.

Clinical characteristics of patients according to current use of medications at 1-year after index stroke.</p

sj-tif-3-msj-10.1177_13524585221109397 – Supplemental material for A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database

Supplemental material, sj-tif-3-msj-10.1177_13524585221109397 for A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database by Jee-Eun Kim, Jin Park and Tae-Jin Song in Multiple Sclerosis Journal</p

sj-tif-2-msj-10.1177_13524585221109397 – Supplemental material for A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database

Supplemental material, sj-tif-2-msj-10.1177_13524585221109397 for A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database by Jee-Eun Kim, Jin Park and Tae-Jin Song in Multiple Sclerosis Journal</p

sj-docx-1-msj-10.1177_13524585221109397 – Supplemental material for A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database

Supplemental material, sj-docx-1-msj-10.1177_13524585221109397 for A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database by Jee-Eun Kim, Jin Park and Tae-Jin Song in Multiple Sclerosis Journal</p